Brief: Applied Molecular Transport Announces Top-Line Phase 2 Results From Market Combination Trial Of Oral AMT-101

Applied Molecular Transport.

06/07/2022 13:45

July 6 (Reuters) - Applied Molecular Transport Inc.
 AMTI.O :
    * APPLIED MOLECULAR TRANSPORT ANNOUNCES TOP-LINE PHASE 2
RESULTS
FROM MARKET COMBINATION TRIAL OF ORAL AMT-101 IN PATIENTS WITH
MODERATE-TO-SEVERE ULCERATIVE COLITIS
    * AMT-101 APPEARED SAFE AND WELL-TOLERATED
    * KEY EFFICACY ENDPOINT OF CLINICAL REMISSION WAS MEASURED
AT 8
WEEKS
    * AMT- CLINICAL REMISSION RATES OBSERVED OF 31.8% IN THOSE
RECEIVING AMT-101 AND ADALIMUMAB VERSUS 33.3% FOR PLACEBO PLUS
ADALIMUMAB AT WEEK 8
    * AMT- DATA FROM THE MARKET TRIAL DID NOT DEMONSTRATE ADDED
CLINICAL BENEFIT IN THE COMBINATION ARM COMPARED TO THE
ADALIMUMAB ALONE ARM AT WEEK 8

Source text for Eikon:  ID:nGNX2b5rHw 
Further company coverage:  AMTI.O